Diamant Thaçi

22.6k total citations · 13 hit papers
375 papers, 13.5k citations indexed

About

Diamant Thaçi is a scholar working on Immunology, Dermatology and Immunology and Allergy. According to data from OpenAlex, Diamant Thaçi has authored 375 papers receiving a total of 13.5k indexed citations (citations by other indexed papers that have themselves been cited), including 243 papers in Immunology, 211 papers in Dermatology and 77 papers in Immunology and Allergy. Recurrent topics in Diamant Thaçi's work include Psoriasis: Treatment and Pathogenesis (225 papers), Dermatology and Skin Diseases (201 papers) and Asthma and respiratory diseases (63 papers). Diamant Thaçi is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (225 papers), Dermatology and Skin Diseases (201 papers) and Asthma and respiratory diseases (63 papers). Diamant Thaçi collaborates with scholars based in Germany, United States and Canada. Diamant Thaçi's co-authors include Kristian Reich, Kim Papp, Andrew Blauvelt, Wolf‐­Henning Boehncke, Ralf J. Ludwig, Roland Kaufmann, C. Paul, Neil M.H. Graham, Emma Guttman‐Yassky and Melinda Gooderham and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nucleic Acids Research.

In The Last Decade

Diamant Thaçi

338 papers receiving 13.3k citations

Hit Papers

Dupilumab Treatment in Adults with Moderate-to-Severe Ato... 2014 2026 2018 2022 2014 2015 2017 2016 2021 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
    2014 1.0k citations Lisa A. Beck, Diamant Thaçi et al. profile →
  2. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
    2015 429 citations Diamant Thaçi, Andrew Blauvelt et al. Journal of the American Academy of Dermatology profile →
  3. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
    2017 413 citations Kristian Reich, Kim Papp et al. profile →
  4. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
    2016 376 citations Kim Papp, Kristian Reich et al. British Journal of Dermatology profile →
  5. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
    2021 350 citations Emma Guttman‐Yassky, Henrique D. Teixeira et al. profile →
  6. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
    2017 344 citations Marjolein de Bruin‐Weller, Diamant Thaçi et al. British Journal of Dermatology profile →
  7. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
    2021 287 citations Jonathan I. Silverberg, Diamant Thaçi et al. profile →
  8. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
    2019 255 citations Emma Guttman‐Yassky, Diamant Thaçi et al. Journal of Allergy and Clinical Immunology profile →
  9. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
    2022 219 citations April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology profile →
  10. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
    2022 173 citations Bruce Strober, Diamant Thaçi et al. Journal of the American Academy of Dermatology profile →
  11. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
    2023 162 citations Jonathan I. Silverberg, Emma Guttman‐Yassky et al. profile →
  12. Lichen sclerosus: The 2023 update
    2023 60 citations Katja Bieber, Diamant Thaçi et al. profile →
  13. A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX
    2025 30 citations Ralf J. Ludwig, Henner Zirpel et al. profile →

Peers

Diamant Thaçi
Comparison fields: 5 of 133
  • Immunology 8.3k
  • Dermatology 7.7k
  • Rheumatology 3.2k
  • Immunology and Allergy 2.7k
  • Physiology 2.5k
Replace Robert Bissonnette with:
Robert Bissonnette Canada
Richard G. Langley Canada
Melinda Gooderham Canada
Wolf‐­Henning Boehncke Germany
Kenneth B. Gordon United States
Kristian Reich Germany
Alan Menter United States
Neil J. Korman United States
Craig L. Leonardi United States
Bruce Strober United States
Robert Bissonnette Canada View profile →
Citations per field, relative to Diamant Thaçi
Diamant Thaçi · 1×
Citations per year, relative to Diamant Thaçi
Diamant Thaçi · 1×

Countries citing papers authored by Diamant Thaçi

Since Specialization
Citations

This map shows the geographic impact of Diamant Thaçi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diamant Thaçi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diamant Thaçi more than expected).

Fields of papers citing papers by Diamant Thaçi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diamant Thaçi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diamant Thaçi. The network helps show where Diamant Thaçi may publish in the future.

Co-authorship network of co-authors of Diamant Thaçi

This figure shows the co-authorship network connecting the top 25 collaborators of Diamant Thaçi. A scholar is included among the top collaborators of Diamant Thaçi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diamant Thaçi. Diamant Thaçi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study results
2025 ·Journal of Allergy and Clinical Immunology ·Diamant Thaçi, Vivian Laquer, Charles Lynde, Adam Reich, Weily Soong, Margitta Worm, (unknown), (unknown), Thomas Litman, (unknown), Martin Olesen, Ole E. Sørensen, Melinda Gooderham
0
2
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
2025 ·Journal of the American Academy of Dermatology ·(unknown), Richard G. Langley, Mark Lebwohl, Bruce Strober, Richard B. Warren, L. Puig, Akimichi Morita, Kenneth B. Gordon, Pablo Fernández‐Peñas, Sarah Kavanagh, (unknown), Jérémy Lambert, Bengt Hoepken, (unknown), Nancy Cross, Diamant Thaçi
1
3
Increased risk of psychiatric disease in patients with prurigo nodularis
2025 ·British Journal of Dermatology ·(unknown), Andreas Recke, Evelyn Gaffal, Jan Philipp Klein, Henner Zirpel, Khalaf Kridin, Diamant Thaçi, Henning Olbrich, Katja Bieber, Ralf J. Ludwig
0
4
Risk of cardiovascular disorders in hidradenitis suppurativa patients: a large‐scale, propensity‐matched global retrospective cohort study
2024 ·International Journal of Dermatology ·Piotr K. Krajewski, Łukasz Matusiak, Sascha Ständer, Diamant Thaçi, Jacek C. Szepietowski, Henner Zirpel
4
5
53999 Efficacy and safety after 52 weeks in psoriasis patients switching to risankizumab after suboptimal response to secukinumab or ixekizumab – a subgroup analysis
2024 ·Journal of the American Academy of Dermatology ·Richard B. Warren, Antonio Costanzo, Neil J. Korman, Simone Rubant, (unknown), (unknown), (unknown), Diamant Thaçi
1
6
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)
2024 ·Journal of the European Academy of Dermatology and Venereology ·Bruce Strober, Andrew Blauvelt, Richard B. Warren, Kim Papp, April W. Armstrong, Kenneth B. Gordon, Akimichi Morita, Andrew Alexis, Mark Lebwohl, Peter Foley, Renata M. Kisa, Elizabeth Colston, Tao Wang, Subhashis Banerjee, Diamant Thaçi
27
7
733 - Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data
2024 ·British Journal of Dermatology ·(unknown), Linda Stein‐Gold, Diamant Thaçi, Andrew Pink, Kim Papp, Franz J. Legat, Vivian Laquer, Soo Yeon Cheong, (unknown), (unknown), Christophe Piketty
0
8
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
2024 ·American Journal of Clinical Dermatology ·Jonathan I. Silverberg, Melinda Gooderham, Amy S. Paller, Mette Deleuran, Christopher G. Bunick, Linda Stein Gold, DirkJan Hijnen, Brian Calimlim, Wan‐Ju Lee, Henrique D. Teixeira, (unknown), Shiyu Zhang, (unknown), Ayman Grada, Andrew M. Platt, Diamant Thaçi
18
9
Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
2023 ·SKIN The Journal of Cutaneous Medicine ·Mark Lebwohl, Richard B. Warren, Howard Sofen, (unknown), C. Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, (unknown), Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt
3
10
POS1161 RITUXIMAB VS. COMBINATION OF RITUXIMAB AND CYCLOPHOSPHAMIDE INDUCTION THERAPY FOR ANCA-ASSOCIATED VASCULITIS: A RETROSPECTIVE STUDY
2023 ·Annals of the Rheumatic Diseases ·(unknown), Sebastian Klapa, Stephan Christian Werth, Ulrich Müller, Gabriela Riemekasten, Martin Nitschke, Diamant Thaçi, Peter Lamprecht
0
11
Chronische Entzündungserkrankungen in Deutschland
2023 ·Zeitschrift für Rheumatologie ·Jan Leipe, Renate Schmelz, Gabriela Riemekasten, Diamant Thaçi, Jörg Henes, Knut Schäkel, Andreas Pinter, Michael Sticherling, Joanna Wegner, Stefano Fusco, (unknown), (unknown), (unknown), Holger Bartz, (unknown), Sandra Schmidt, Bimba F. Hoyer
3
12
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
2023 ·British Journal of Dermatology ·Kenneth B. Gordon, Richard G. Langley, Richard B. Warren, Yukari Okubo, David Rosmarin, Mark Lebwohl, Luke Peterson, Cynthia Madden, Dirk De Cuyper, O. Davies, Diamant Thaçi
14
13
Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes
2022 ·Rheumatology and Therapy ·Eugen Feist, Xenofon Baraliakos, Frank Behrens, Diamant Thaçi, T. Klopsch, (unknown), (unknown), Klaus Pietzner, (unknown), Peter‐Andreas Löschmann
12
14
Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial
2021 ·British Journal of Dermatology ·Diamant Thaçi, Kilian Eyerich, Andreas Pinter, Michael Sebastian, Kristina Unnebrink, Simone Rubant, David Williams, Peter Weisenseel
15
15
Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
2021 ·Dermatology and Therapy ·Gil Yosipovitch, Marjolein de Bruin‐Weller, April W. Armstrong, Jashin J. Wu, Pedro Herranz, Diamant Thaçi, Dimittri Delevry, (unknown), (unknown), Brad Shumel, Ana B. Rossi, Jingdong Chao
7
16
International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale
2020 ·BMJ Open ·Katrina Abuabara, Jonathan I. Silverberg, Eric L. Simpson, Amy S. Paller, Lawrence F. Eichenfield, Robert Bissonnette, James G. Krueger, John E. Harris, (unknown), Stephanie Watkins, (unknown), Diamant Thaçi, Emma Guttman‐Yassky
7
17
Dupilumab Improves Outcomes of Concurrent Asthma and Chronic Sino-Nasal Conditions in Patients With Atopic Dermatitis—a Pooled Analysis of Four Phase 3 Studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFÉ)
2019 ·Journal of Allergy and Clinical Immunology ·Mark Boguniewicz, Diamant Thaçi, Peter Lio, Thomas Hultsch, Ana B. Rossi, Laurent Eckert, Abhijit Gadkari, Brad Shumel, Qiuyue Chen, Zhen Chen, Marius Ardeleanu
4
18
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial breakdown →
2019 ·Journal of Allergy and Clinical Immunology ·Emma Guttman‐Yassky, Diamant Thaçi, Aileen L. Pangan, Hwanhee Hong, Kim Papp, Kristian Reich, Lisa A. Beck, Mohamed‐Eslam F. Mohamed, Ahmed A. Othman, J. Anderson, Yihua Gu, Henrique D. Teixeira, Jonathan I. Silverberg
255
19
[Psoriatic arthritis : Overview of drug therapy options and administration characteristics].
2017 ·PubMed ·(unknown), Diamant Thaçi, J. Wollenhaupt, K. Krüger
6
20
Effects of apremilast on pruritus in patients with moderate to severe plaque psoriasis : results from the ESTEEM 1 and 2 trials
2015 ·Ghent University Academic Bibliography (Ghent University) ·Diamant Thaçi, Gil Yosipovitch, Kim Papp, Jerry Bagel, (unknown), Jo Lambert, Carlos Montilla, Mark Goodfield, (unknown), Robert M. Day, Giampiero Girolomoni
1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert Bissonnette Breakdown of academic impact, for papers by Richard G. Langley Breakdown of academic impact, for papers by Melinda Gooderham Breakdown of academic impact, for papers by Wolf‐­Henning Boehncke Breakdown of academic impact, for papers by Kenneth B. Gordon Breakdown of academic impact, for papers by Kristian Reich Breakdown of academic impact, for papers by Alan Menter Breakdown of academic impact, for papers by Neil J. Korman Breakdown of academic impact, for papers by Craig L. Leonardi Breakdown of academic impact, for papers by Bruce Strober
Rankless by CCL
2026